In Germany, carriers of pathogenic variants in ATM, BRCA1, BRCA2, BARD1, BRIP1, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, and TP53 are eligible for the intensified breast cancer surveillance (IBCS) program, which includes annual breast MRI as a core component [1]. The gene discussed is BARD1; the disease is breast carcinoma.